John Fuqua
Pediatric Endocrinology · Indianapolis, INNPI 1669587184
Payments from drug & device makers
$447,394in general payments, 2019–2025
Across 1,061 payments — averaging $421.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$249K
- Pfizer$121K
- Biomarin Pharmaceutical Inc.$33K
- Ascendis Pharma Endocrinology Inc$25K
- Merck$18K
- Tolmar Pharmaceuticals, Inc.$2K
General payments by program year
19
20
21
22
23
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 1,029 | $248,821 |
| Pfizer | 8 | $120,733 |
| Biomarin Pharmaceutical Inc. | 1 | $33,337 |
| Ascendis Pharma Endocrinology Inc | 4 | $24,972 |
| Merck | 18 | $17,926 |
| Tolmar Pharmaceuticals, Inc. | 1 | $1,605 |
How this compares
$447,394 in reported general payments places this provider in the 85th percentile of 27 pediatric endocrinology providers in Indiana.
Other pediatric endocrinology in Indianapolis
- Erik ImelIndianapolis$2.7M
- Linda di MeglioIndianapolis$1.5M
- Tamara HannonIndianapolis$561K
- Gordon CutlerIndianapolis$305K
- Emily SimsIndianapolis$236K
- Erica EugsterIndianapolis$104K
- Jamie FeltonIndianapolis$34K
- Rebecca AguirreIndianapolis$13K
- Hebatullah IsmailIndianapolis$9K
- Eric ChangIndianapolis$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.